The malignant behavior of neuroblastomas differs markedly: some regress spontaneously, others can be eradicated with therapy, and still others respond temporarily or not at all to therapy.
The aims of this investigation are to further understand the molecular basis for these differences and to use this information to improve diagnosis and prognostication. The relationship of oncogene expression, tumor cell proliferation, and patient survival will be examined and monoclonal antibodies against tumor cell markers that define neuroblastoma and its biologically and therapeutically relevant subsets will be characterized. Laboratory and clinical resources include 1) panels of monoclonal antibodies, oncogene probes, and human neuroblastoma cell lines; 2) microcomputer-based digital image microscopy; 3) a unique and enlarging library of tumor and bone marrow specimens; and 4) a computerized clinical database for patients being studied. Our previous studies of the N-myc oncogene documented that tumors with genomic amplification rapidly progress; that the gene product is a nuclear phosphoprotein (62 and 64 kd); and that tumors with greater than 10 copies of the gene express high amounts of the protein. Our new studies will determine if a significant percentage of non- amplified, aggressive tumors express N-myc and if progression of amplified or non-amplified tumors is associated with increased expression. Additional important experiments aim to identify other oncogenes that are activated, particularly in those aggressive tumors that do not express N-myc. A major consequence of activating N-myc and other oncogenes may be to confer greater proliferative capacity, which results in a highly malignant phenotype. We shall seek support for this hypothesis by determining if there is a relationship between N-myc expression and antigens that define the proliferative state of tumor cells. By immunophenotyping, we shall determine if oncogene, differentiation antigen, and histocompatibility antigen expression defines biologically and therapeutically relevant subtypes of neuroblastomas and primitive neuroectodermal tumors. Our prognostic efforts seek to further improve accuracy by focusing on antigenic markers for oncogene proteins and cell proliferation- related molecules. The relative importance of known factors and those to be tested will be determined by multivariate analysis. Throughout our studies of prognosis, we shall determine if previously unrecognized subsets of patients emerge as a result of new therapies. We anticipate that these studies will contribute to the understanding of neuroblastoma and ultimately to therapeutic modalities that are more effective and specific.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA022794-13
Application #
3165941
Study Section
Experimental Immunology Study Section (EI)
Project Start
1978-02-01
Project End
1993-05-31
Budget Start
1989-06-01
Budget End
1990-05-31
Support Year
13
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Children's Hospital of Los Angeles
Department
Type
DUNS #
094878337
City
Los Angeles
State
CA
Country
United States
Zip Code
90027
Metelitsa, Leonid S; Wu, Hong-Wei; Wang, Hong et al. (2004) Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J Exp Med 199:1213-21
Shimada, Hiroyuki; Nakagawa, Atsuko; Peters, Julius et al. (2004) TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance. Cancer 101:1873-81
Metelitsa, L S; Weinberg, K I; Emanuel, P D et al. (2003) Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia 17:1068-77
Loza, Matthew J; Metelitsa, Leonid S; Perussia, Bice (2002) NKT and T cells: coordinate regulation of NK-like phenotype and cytokine production. Eur J Immunol 32:3453-62
Rudnick, E; Khakoo, Y; Antunes, N L et al. (2001) Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study. Med Pediatr Oncol 36:612-22
Metelitsa, L S; Naidenko, O V; Kant, A et al. (2001) Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol 167:3114-22
Seeger, R C; Reynolds, C P; Gallego, R et al. (2000) Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study. J Clin Oncol 18:4067-76
Nickerson, H J; Matthay, K K; Seeger, R C et al. (2000) Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. J Clin Oncol 18:477-86
Perez, C A; Matthay, K K; Atkinson, J B et al. (2000) Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. J Clin Oncol 18:18-26
DuBois, S G; Kalika, Y; Lukens, J N et al. (1999) Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 21:181-9

Showing the most recent 10 out of 47 publications